Virbac Toekomstige groei
Future criteriumcontroles 1/6
Virbac zal naar verwachting groeien in winst en omzet met respectievelijk 10.3% en 5.2% per jaar. De winst per aandeel zal naar verwachting groeien met 10% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 12.9% zijn.
Belangrijke informatie
10.3%
Groei van de winst
10.02%
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 16.0% |
| Inkomstengroei | 5.2% |
| Toekomstig rendement op eigen vermogen | 12.85% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 21 May 2026 |
Recente toekomstige groei-updates
Analyseartikel • Sep 17
Analysts Have Made A Financial Statement On Virbac SA's (EPA:VIRP) First-Quarter Report
Shareholders might have noticed that Virbac SA ( EPA:VIRP ) filed its quarterly result this time last week. The early...Analyseartikel • Sep 18
Virbac SA Just Beat Revenue Estimates By 6.0%
It's been a good week for Virbac SA ( EPA:VIRP ) shareholders, because the company has just released its latest...Recent updates
Narratiefupdate • May 09
VIRP: Human Animal Bond Partnership Will Support Future Upside Repricing
Analysts have made a small upward adjustment to their Virbac target, lifting fair value from about €412.33 to €413.00. This reflects updated assumptions around the discount rate, revenue growth, profit margin and future P/E.Narratiefupdate • Mar 11
VIRP: Human Animal Bond Partnership Will Support 2026 Outlook Repricing
Analysts have made a small adjustment to their Virbac price target to reflect marginal tweaks in fair value, growth and margin assumptions, trimming it by about €0.50 to €412.33. What's in the News Virbac entered a new partnership with the Human Animal Bond Research Institute to support efforts that strengthen the human animal bond and its impact on companion animal and human health, focusing on science, education and collaboration (Key Developments).Narratiefupdate • Feb 25
VIRP: Stable Assumptions And 2026 Guidance Will Support Bullish Repricing
Analysts have maintained their Virbac price target at €412.82, indicating unchanged views on fair value, discount rate, growth assumptions, and margin expectations for the company. What's in the News Virbac entered a partnership with the Human Animal Bond Research Institute (HABRI) to support efforts that strengthen the human animal bond and its impact on companion animal and human health, with a focus on science, education and collaboration (Key Developments).Narratiefupdate • Feb 11
VIRP: Stable Inputs And 2026 Guidance Will Support Bullish Repricing
Analysts have kept Virbac's fair value estimate steady at €412.82 per share, with only small technical adjustments to inputs such as the discount rate and assumed future P/E informing this unchanged price target. What's in the News Virbac issued earnings guidance for 2026, including the impact of the Thyronorm acquisition, with revenue growth expected to be between 5.5% and 7.5% at constant rates and scope (Key Developments).Narratiefupdate • Jan 26
VIRP: Broad Regional Execution And 2026 Outlook Will Support Bullish Repricing
Narrative Update The analyst price target for Virbac has been raised from €390 to €415, with analysts citing accelerated growth across all regions as the key driver of this change. Analyst Commentary Analysts lifting their price target on Virbac to €415 from €390 are focusing on how the company is executing its growth plans across regions and what that could mean for valuation and risk.Narratiefupdate • Jan 07
VIRP: Broad Regional Acceleration Will Support Upgraded Buy Rating Into 2025
Narrative Update on Virbac Analysts have increased their price target on Virbac to €415 from €390, citing what they describe as accelerated growth across all regions as the key driver for their updated view. Analyst Commentary Recent research points to a more constructive stance on Virbac, with analysts raising their price target to €415 from €390 as they reassess the company’s growth profile.Narratiefupdate • Dec 23
VIRP: Broad Regional Acceleration Will Sustain Upgraded Buy Rating Through 2025
Analysts have raised their price target on Virbac from EUR 390 to EUR 415, citing an acceleration in the company’s growth across all regions. Analyst Commentary Bullish Takeaways Bullish analysts view the upgrade to a higher price target as a reflection of stronger than expected execution in scaling operations across all regions.Narratiefupdate • Dec 09
VIRP: Broad Regional Momentum Will Support Upgraded Buy Rating Through 2025
Analysts have raised their price target on Virbac by EUR 25 to EUR 415, citing an acceleration in the company’s growth across all regions. Analyst Commentary Following the recent upgrade, research coverage has focused on the sustainability of Virbac’s growth acceleration and its implications for valuation.Narratiefupdate • Nov 25
VIRP: Accelerated Regional Momentum Will Sustain an Upgraded Bullish Outlook for 2025
Analysts have raised Virbac's price target from €390 to €415, citing accelerated growth across all regions as the key driver for their more positive outlook. Analyst Commentary Bullish Takeaways Bullish analysts cite a clear acceleration in Virbac's growth across all geographic regions, which supports a more positive outlook for the company.Narratiefupdate • Nov 07
VIRP: Accelerated Regional Expansion Will Drive Upgraded Earnings Outlook Next Year
Narrative Update on Virbac Analysts have raised Virbac's price target from €398 to €403, citing accelerated growth across all regions as the primary driver for this upward revision. Analyst Commentary The most recent research notes reflect increased optimism around Virbac's trajectory, with upward revisions to both rating and price targets.Analyseartikel • Oct 05
Is There An Opportunity With Virbac SA's (EPA:VIRP) 43% Undervaluation?
Key Insights Virbac's estimated fair value is €563 based on 2 Stage Free Cash Flow to Equity Virbac's €323 share price...Analyseartikel • Sep 17
Analysts Have Made A Financial Statement On Virbac SA's (EPA:VIRP) First-Quarter Report
Shareholders might have noticed that Virbac SA ( EPA:VIRP ) filed its quarterly result this time last week. The early...Analyseartikel • Aug 30
There's Reason For Concern Over Virbac SA's (EPA:VIRP) Price
Virbac SA's ( EPA:VIRP ) price-to-earnings (or "P/E") ratio of 19.3x might make it look like a sell right now compared...Analyseartikel • Jun 23
Is There An Opportunity With Virbac SA's (EPA:VIRP) 46% Undervaluation?
Key Insights Virbac's estimated fair value is €601 based on 2 Stage Free Cash Flow to Equity Virbac's €324 share price...Analyseartikel • May 18
Virbac SA (EPA:VIRP) Investors Are Less Pessimistic Than Expected
When close to half the companies in France have price-to-earnings ratios (or "P/E's") below 15x, you may consider...Analyseartikel • Apr 30
Virbac (EPA:VIRP) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Nieuw narratief • Mar 16
Future R&D And Facility Expansion Will Introduce New Products In Pet Care And Pharmaceuticals
Strategic R&D investments and facility expansions aim to drive innovation, operational efficiency, and future revenue growth, potentially enhancing profitability.Analyseartikel • Jan 24
Earnings Not Telling The Story For Virbac SA (EPA:VIRP)
Virbac SA's ( EPA:VIRP ) price-to-earnings (or "P/E") ratio of 17.9x might make it look like a sell right now compared...Analyseartikel • Oct 06
An Intrinsic Calculation For Virbac SA (EPA:VIRP) Suggests It's 47% Undervalued
Key Insights The projected fair value for Virbac is €699 based on 2 Stage Free Cash Flow to Equity Virbac is estimated...Analyseartikel • Sep 18
Virbac SA Just Beat Revenue Estimates By 6.0%
It's been a good week for Virbac SA ( EPA:VIRP ) shareholders, because the company has just released its latest...Analyseartikel • Aug 31
Unpleasant Surprises Could Be In Store For Virbac SA's (EPA:VIRP) Shares
With a price-to-earnings (or "P/E") ratio of 24x Virbac SA ( EPA:VIRP ) may be sending very bearish signals at the...Analyseartikel • Jun 15
Why We Think Virbac SA's (EPA:VIRP) CEO Compensation Is Not Excessive At All
Key Insights Virbac's Annual General Meeting to take place on 21st of June Salary of €379.0k is part of CEO Sebastien...Analyseartikel • Jun 10
Are Investors Undervaluing Virbac SA (EPA:VIRP) By 34%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Virbac fair value estimate is €551 Virbac's €363 share price...Analyseartikel • May 21
Virbac SA (EPA:VIRP) Investors Are Less Pessimistic Than Expected
With a price-to-earnings (or "P/E") ratio of 24.2x Virbac SA ( EPA:VIRP ) may be sending bearish signals at the moment...Analyseartikel • Mar 22
Here's What Analysts Are Forecasting For Virbac SA (EPA:VIRP) After Its Yearly Results
Last week saw the newest yearly earnings release from Virbac SA ( EPA:VIRP ), an important milestone in the company's...Analyseartikel • Jan 18
Is Virbac SA (EPA:VIRP) Trading At A 23% Discount?
Key Insights The projected fair value for Virbac is €440 based on 2 Stage Free Cash Flow to Equity Virbac's €340 share...Analyseartikel • Dec 27
Virbac SA's (EPA:VIRP) Shares Climb 25% But Its Business Is Yet to Catch Up
Virbac SA ( EPA:VIRP ) shares have continued their recent momentum with a 25% gain in the last month alone. Looking...Analyseartikel • Oct 19
Virbac (EPA:VIRP) Has A Pretty Healthy Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Sep 26
Is There An Opportunity With Virbac SA's (EPA:VIRP) 40% Undervaluation?
Key Insights Virbac's estimated fair value is €411 based on 2 Stage Free Cash Flow to Equity Current share price of...Analyseartikel • Sep 05
Here's Why We Think Virbac (EPA:VIRP) Is Well Worth Watching
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analyseartikel • Jun 20
A Look At The Fair Value Of Virbac SA (EPA:VIRP)
Key Insights The projected fair value for Virbac is €337 based on 2 Stage Free Cash Flow to Equity Current share price...Analyseartikel • May 31
Does Virbac (EPA:VIRP) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analyseartikel • Apr 09
Is Virbac (EPA:VIRP) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Feb 28
Are Investors Undervaluing Virbac SA (EPA:VIRP) By 34%?
Key Insights The projected fair value for Virbac is €437 based on 2 Stage Free Cash Flow to Equity Virbac's €288 share...Analyseartikel • Nov 25
Virbac SA (EPA:VIRP) Shares Could Be 50% Below Their Intrinsic Value Estimate
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Virbac SA ( EPA:VIRP...Analyseartikel • Oct 14
Does Virbac (EPA:VIRP) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analyseartikel • Aug 07
An Intrinsic Calculation For Virbac SA (EPA:VIRP) Suggests It's 42% Undervalued
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Virbac SA ( EPA:VIRP...Analyseartikel • Jun 26
These 4 Measures Indicate That Virbac (EPA:VIRP) Is Using Debt Safely
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • May 01
Virbac SA (EPA:VIRP) Shares Could Be 38% Below Their Intrinsic Value Estimate
How far off is Virbac SA ( EPA:VIRP ) from its intrinsic value? Using the most recent financial data, we'll take a look...Analyseartikel • Mar 26
We Think Virbac (EPA:VIRP) Can Manage Its Debt With Ease
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyseartikel • Jan 26
Virbac SA (EPA:VIRP) Shares Could Be 36% Below Their Intrinsic Value Estimate
How far off is Virbac SA ( EPA:VIRP ) from its intrinsic value? Using the most recent financial data, we'll take a look...Analyseartikel • Dec 28
Here's Why I Think Virbac (EPA:VIRP) Is An Interesting Stock
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...Analyseartikel • Oct 27
A Look At The Fair Value Of Virbac SA (EPA:VIRP)
Does the October share price for Virbac SA ( EPA:VIRP ) reflect what it's really worth? Today, we will estimate the...Analyseartikel • Oct 12
Is Virbac (EPA:VIRP) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Sep 26
Here's Why I Think Virbac (EPA:VIRP) Might Deserve Your Attention Today
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2028 | 1,715 | 210 | 168 | 275 | 6 |
| 12/31/2027 | 1,640 | 192 | 125 | 247 | 9 |
| 12/31/2026 | 1,558 | 167 | 72 | 211 | 4 |
| 12/31/2025 | 1,465 | 151 | 97 | 199 | N/A |
| 9/30/2025 | 1,449 | 142 | 93 | 197 | N/A |
| 6/30/2025 | 1,433 | 133 | 88 | 195 | N/A |
| 3/31/2025 | 1,415 | 139 | 106 | 200 | N/A |
| 12/31/2024 | 1,397 | 145 | 124 | 204 | N/A |
| 9/30/2024 | 1,368 | 143 | 99 | 171 | N/A |
| 6/30/2024 | 1,339 | 141 | 74 | 139 | N/A |
| 3/31/2024 | 1,293 | 131 | 66 | 129 | N/A |
| 12/31/2023 | 1,247 | 121 | 59 | 119 | N/A |
| 9/30/2023 | 1,229 | 120 | 69 | 124 | N/A |
| 6/30/2023 | 1,210 | 119 | 78 | 129 | N/A |
| 3/31/2023 | 1,213 | 121 | 62 | 114 | N/A |
| 12/31/2022 | 1,216 | 122 | 45 | 99 | N/A |
| 9/30/2022 | 1,184 | 120 | 38 | 91 | N/A |
| 6/30/2022 | 1,151 | 119 | 31 | 84 | N/A |
| 3/31/2022 | 1,107 | 116 | 57 | 107 | N/A |
| 12/31/2021 | 1,064 | 113 | 83 | 130 | N/A |
| 9/30/2021 | 1,025 | 137 | 80 | 122 | N/A |
| 6/30/2021 | 985 | 161 | 77 | 113 | N/A |
| 3/31/2021 | 960 | 148 | 83 | 116 | N/A |
| 12/31/2020 | 934 | 136 | 90 | 119 | N/A |
| 9/30/2020 | 944 | 104 | 106 | 133 | N/A |
| 6/30/2020 | 953 | 72 | 123 | 146 | N/A |
| 3/31/2020 | 946 | 62 | 116 | 139 | N/A |
| 12/31/2019 | 938 | 52 | 109 | 132 | N/A |
| 9/30/2019 | 921 | 43 | N/A | 119 | N/A |
| 6/30/2019 | 903 | 34 | N/A | 106 | N/A |
| 3/31/2019 | 886 | 27 | N/A | 95 | N/A |
| 12/31/2018 | 869 | 20 | N/A | 84 | N/A |
| 9/30/2018 | 862 | 8 | N/A | 93 | N/A |
| 6/30/2018 | 854 | -4 | N/A | 103 | N/A |
| 3/31/2018 | 858 | -3 | N/A | 105 | N/A |
| 12/31/2017 | 862 | -3 | N/A | 108 | N/A |
| 9/30/2017 | 871 | 16 | N/A | 112 | N/A |
| 6/30/2017 | 879 | 35 | N/A | 117 | N/A |
| 3/31/2017 | 876 | 35 | N/A | 130 | N/A |
| 12/31/2016 | 872 | 35 | N/A | 142 | N/A |
| 9/30/2016 | 861 | 30 | N/A | 119 | N/A |
| 6/30/2016 | 850 | 26 | N/A | 95 | N/A |
| 3/31/2016 | 851 | 18 | N/A | 71 | N/A |
| 12/31/2015 | 853 | 9 | N/A | 46 | N/A |
| 9/30/2015 | 846 | 21 | N/A | 59 | N/A |
| 6/30/2015 | 839 | 32 | N/A | 72 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei VIRP ( 10.3% per jaar) ligt boven de spaarquote ( 2.5% ).
Winst versus markt: De winst van VIRP ( 10.3% per jaar) zal naar verwachting langzamer groeien dan de markt French ( 12.4% per jaar).
Hoge groeiwinsten: De winst van VIRP zal naar verwachting groeien, maar niet aanzienlijk.
Omzet versus markt: De omzet van VIRP ( 5.2% per jaar) zal naar verwachting langzamer groeien dan de markt French ( 5.6% per jaar).
Hoge groei-inkomsten: De omzet van VIRP ( 5.2% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen VIRP zal naar verwachting over 3 jaar laag zijn ( 12.9 %).
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/21 14:15 |
| Aandelenkoers aan het einde van de dag | 2026/05/21 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Virbac SA wordt gevolgd door 12 analisten. 9 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Delphine Le Louet | Bernstein |
| Laurent Gelebart | BNP Paribas |
| Arnaud Cadart | CIC Market Solutions (ESN) |